Our approach to
Small easy to use device (the size of a credit card), fits in your pocket and when held with fingers on the sensors analyses real-time ECG signals.
Point in time ECG snapshot configurable up to 10 minutes monitoring duration.
Converts to a 2 electrode 24hr on-body monitor for clinical use.
is a TGA approved Class 2a medical device.
People per year are diagnosed with AFib
Hospitalizations caused by AFib every year
Deaths related to AFib every year
Annual economic burden of AFib in US
Clinical / Pharmacy Applications
Cardiac arrhythmia detections
Post dialysis cardiac assessment
Medicine impact reviews
Sport & Fitness Use
Personal training and tracking
PRECISION MEDICINE HEALTHCARE
Clinical Decision Support for Healthcare Professionals
Is the patient likely to develop this disease?
What can be done to reduce the likelihood of developing it?
Does the patient have the disease now?
Which therapeutic pathways would be best for this patient?
Drug profiles for cardiovascular disease treatments
The use of a patient's genetic information to determine risk, prevention, diagnosis and treatment.
Our platform is the enabler of Precision Cardiology.
Genes associated with cardiac disease including over 40 genes related to Stroke
Cardiac diseases diagnosed and managed in the platform
Clinical risk scoring models
Heart disease drug profiles in clinical use
ECG MONITORING used by
CLINICIANS and CONSUMERS
DIRECT TO CONSUMER
Consumers are able to purchase our hand-held device and use the mobile app for a subscription fee. This allows the general consumer to access the clinical-grade device and service used by professionals. An easy to read report is generated with summary at any time with unlimited reports in the subscription. Should the monitoring session detect an issue, the report can be sent to our team of cardiac specialists for verification of the automated report and signed-off by our cardiologists.
This is an exciting new way to have much greater control over your health and have professional assessment when needed.
Biosignals Diagnostics provides a cardiac monitoring service directly to cardiologists and primary healthcare physicians. Our cardiologists assess and sign-off the report.
Heart disease has many contributing factors. Our approach uses the many aspects of patient health and the complex interactions of these factors to assess patient risk, guide prevention, diagnose, treat and manage heart disease and stroke. Biosignals Diagnostics is developing a specialised comprehensive platform for this purpose. By incorporating data from the many lifestyle and biologic factors that drive these diseases, our approach delivers richer decision support for clinical diagnostic and treatment sequencing. The rich data in our platform becomes a high-value asset in its own right and can be used as a clinical resource, or in pharmaceutical development. It also enables development of our
proprietary “cardio-genetic signatures” which will bring greater clarity in the deepening relationship between genetics and heart disease. The platform architecture accommodates many data sources from consumer technologies such as phones and watches in addition to medical diagnostics data from imaging, bio-markers, genomics, ECG, blood pressure and oxygen levels. One of our key platform differentiators however is the intelligent clinical learning engine.
We aim to reduce disease burden, improve patient outcomes and reduce healthcare costs of cardiac disease and stroke through the validated use of precision cardiology.
Cardiac monitoring is a primary diagnostic tool to detect Atrial Fibrillation and other deadly arrhythmias, however current wearable cardiac monitors have limitations diagnosing the disease and often fail to provide Health Care Professionals with timely diagnostically actionable information.
Consistent with our vision we are building solutions to address the the shortcomings of current devices on the market where detection of intermittent arrhythmias is severely limited. To avoid the use of implantable cardiac loop monitors, we are building the next generation of mobile cardiac telemetry devices.